Faust Elizabeth 4

What Happened

• Elizabeth Faust, a director of Biomea Fusion, was granted a derivative award (stock option) covering 196,299 underlying shares on 2026-06-10. The Form 4 reports an acquisition price of $0.00 for the award (derivative transaction), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12.
• Reported amount: 196,299 underlying shares (derivative award) at $0.00.
• Shares owned after transaction: not specified in this filing.
• Vesting note (footnote F1): the shares underlying the option will vest in full on the earlier of (i) the one‑year anniversary of the grant or (ii) immediately prior to the issuer's next annual stockholders' meeting, subject to Faust's continued service.
• Filing timeliness: Form filed two days after the transaction date; filing does not indicate lateness flags.

Context

• This was a grant of a derivative award (stock option), not an open‑market purchase or sale. The filing does not show any immediate exercise or sale of shares. Grants like this are common for employee/director compensation and do not by themselves indicate a decision to buy or sell stock in the open market.